申请人:Heptares Therapeutics Limited
公开号:US10246432B2
公开(公告)日:2019-04-02
The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
本文公开的内容涉及式中 R1、R2、R3 和 R4 以及 n 在本文中定义的新型化合物,以及它们在治疗、预防、改善、控制或降低与调节 mGlu5 受体功能相关的炎症、神经或精神疾病风险方面的用途。